Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1992-9-10
|
pubmed:abstractText |
The aim of this study was to investigate the influence of oral administration of OK-432 on the tumor growth of tumor-bearing mice. In addition, the changing pattern of the splenic lymphocyte subsets of tumor-bearing mice was evaluated by flow cytometry. OK-432 at a dose of 0.1, 1 or 10 KE was administered orally every 3 days or every other day for 30 days to subcutaneously Meth A tumor-inoculated mice. The tumor growth was significantly inhibited in the 1 KE every 3 days group, in the 1 KE every other day group and in the 10 KE every 3 days group. In the 10 KE every other day group, OK-432 inhibited the tumor growth on days 10 and 20, while the agent did not show a marked inhibitory effect on day 30. The percentages of splenic L3T4-positive cells and splenic asialo GM1-positive cells were significantly increased in the 1 KE every other day group, while the Lyt2+/Thy1.2+ ratio was decreased. On the other hand, in the 10 KE every other day group, OK-432 showed no effect on the percentages of splenic L3T4-positive cells and Lyt2+/Thy1.2+ ratio on days 20 and 30. Our results suggest that the antitumor effect of oral administration of OK-432 may be correlated with the changing pattern of L3T4-positive cells and Lyt2+/Thy1.2+ ratio.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Ly,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Surface,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Thy-1,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/G(M1) Ganglioside,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Picibanil,
http://linkedlifedata.com/resource/pubmed/chemical/asialo GM1 ganglioside
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0910-5050
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
83
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
656-60
|
pubmed:dateRevised |
2003-11-14
|
pubmed:meshHeading |
pubmed-meshheading:1353756-Administration, Oral,
pubmed-meshheading:1353756-Animals,
pubmed-meshheading:1353756-Antigens, Ly,
pubmed-meshheading:1353756-Antigens, Surface,
pubmed-meshheading:1353756-Antigens, Thy-1,
pubmed-meshheading:1353756-Antineoplastic Agents,
pubmed-meshheading:1353756-Fibrosarcoma,
pubmed-meshheading:1353756-Flow Cytometry,
pubmed-meshheading:1353756-G(M1) Ganglioside,
pubmed-meshheading:1353756-Lymphocyte Subsets,
pubmed-meshheading:1353756-Male,
pubmed-meshheading:1353756-Membrane Glycoproteins,
pubmed-meshheading:1353756-Mice,
pubmed-meshheading:1353756-Mice, Inbred BALB C,
pubmed-meshheading:1353756-Picibanil,
pubmed-meshheading:1353756-Spleen
|
pubmed:year |
1992
|
pubmed:articleTitle |
The changing pattern of the splenic lymphocyte subsets in tumor-bearing mice after oral treatment with OK-432.
|
pubmed:affiliation |
First Department of Surgery, Okayama University Medical School.
|
pubmed:publicationType |
Journal Article
|